These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 28612419)

  • 1. Striking a balance between quality and cost in PCI.
    Kimmelstiel C; Udelson JE
    Catheter Cardiovasc Interv; 2017 Jun; 89(7):1213-1214. PubMed ID: 28612419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost awareness decreases total percutaneous coronary intervention procedural cost: The SHOPPING (Show How Options in Price for Procedures Can Be Influenced Greatly) trial.
    Asher E; Mansour J; Wheeler A; Kendrick D; Cunningham M; Parikh S; Zidar D; Harford T; Simon DI; Kashyap VS
    Catheter Cardiovasc Interv; 2017 Jun; 89(7):1207-1212. PubMed ID: 27862875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs of transradial percutaneous coronary intervention.
    Amin AP; House JA; Safley DM; Chhatriwalla AK; Giersiefen H; Bremer A; Hamon M; Baklanov DV; Aluko A; Wohns D; Mathias DW; Applegate RA; Cohen DJ; Marso SP
    JACC Cardiovasc Interv; 2013 Aug; 6(8):827-34. PubMed ID: 23871512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of percutaneous coronary intervention with drug-eluting stents versus bypass surgery for patients with 3-vessel or left main coronary artery disease: final results from the Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) trial.
    Cohen DJ; Osnabrugge RL; Magnuson EA; Wang K; Li H; Chinnakondepalli K; Pinto D; Abdallah MS; Vilain KA; Morice MC; Dawkins KD; Kappetein AP; Mohr FW; Serruys PW;
    Circulation; 2014 Sep; 130(14):1146-57. PubMed ID: 25085960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Costs Associated With Access Site and Same-Day Discharge Among Medicare Beneficiaries Undergoing Percutaneous Coronary Intervention: An Evaluation of the Current Percutaneous Coronary Intervention Care Pathways in the United States.
    Amin AP; Patterson M; House JA; Giersiefen H; Spertus JA; Baklanov DV; Chhatriwalla AK; Safley DM; Cohen DJ; Rao SV; Marso SP
    JACC Cardiovasc Interv; 2017 Feb; 10(4):342-351. PubMed ID: 28231901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of percutaneous coronary intervention versus bypass surgery from a Dutch perspective.
    Osnabrugge RL; Magnuson EA; Serruys PW; Campos CM; Wang K; van Klaveren D; Farooq V; Abdallah MS; Li H; Vilain KA; Steyerberg EW; Morice MC; Dawkins KD; Mohr FW; Kappetein AP; Cohen DJ;
    Heart; 2015 Dec; 101(24):1980-8. PubMed ID: 26552756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving the quality of percutaneous revascularisation in patients with multivessel disease in Australia: cost-effectiveness, public health implications, and budget impact of FFR-guided PCI.
    Siebert U; Arvandi M; Gothe RM; Bornschein B; Eccleston D; Walters DL; Rankin J; De Bruyne B; Fearon WF; Pijls NH; Harper R
    Heart Lung Circ; 2014 Jun; 23(6):527-33. PubMed ID: 24560401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Facility-Level Variation in Hospitalization, Mortality, and Costs in the 30 Days After Percutaneous Coronary Intervention: Insights on Short-Term Healthcare Value From the Veterans Affairs Clinical Assessment, Reporting, and Tracking System (VA CART) Program.
    Bradley SM; O'Donnell CI; Grunwald GK; Liu CF; Hebert PL; Maddox TM; Jesse RL; Fihn SD; Rumsfeld JS; Ho PM
    Circulation; 2015 Jul; 132(2):101-8. PubMed ID: 25951833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient and Physician Perspectives on Public Reporting of Mortality Ratings for Percutaneous Coronary Intervention in New York State.
    Fernandez G; Narins CR; Bruckel J; Ayers B; Ling FS
    Circ Cardiovasc Qual Outcomes; 2017 Sep; 10(9):. PubMed ID: 28893831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of high cost after percutaneous coronary intervention: A review from Japanese multicenter registry overviewing the influence of procedural complications.
    Inohara T; Numasawa Y; Higashi T; Ueda I; Suzuki M; Hayashida K; Yuasa S; Maekawa Y; Fukuda K; Kohsaka S
    Am Heart J; 2017 Dec; 194():61-72. PubMed ID: 29223436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial.
    Cohen DJ; Lincoff AM; Lavelle TA; Chen HL; Bakhai A; Berezin RH; Jackman D; Sarembock IJ; Topol EJ
    J Am Coll Cardiol; 2004 Nov; 44(9):1792-800. PubMed ID: 15519009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Future of the PCI Readmission Metric.
    Wasfy JH; Yeh RW
    Circ Cardiovasc Qual Outcomes; 2016 Mar; 9(2):186-9. PubMed ID: 26812931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic and clinical outcomes of a physician-led continuous quality improvement intervention in the delivery of percutaneous coronary intervention.
    Rihal CS; Kamath CC; Holmes DR; Reller MK; Anderson SS; McMurtry EK; Long KH
    Am J Manag Care; 2006 Aug; 12(8):445-52. PubMed ID: 16886887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of Care at Hospitals Identified as Outliers in Publicly Reported Mortality Statistics for Percutaneous Coronary Intervention.
    Waldo SW; McCabe JM; Kennedy KF; Zigler CM; Pinto DS; Yeh RW
    Circulation; 2017 May; 135(20):1897-1907. PubMed ID: 28249879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of percutaneous coronary intervention with cobalt-chromium everolimus eluting stents versus bare metal stents: Results from a patient level meta-analysis of randomized trials.
    Ferko N; Ferrante G; Hasegawa JT; Schikorr T; Soleas IM; Hernandez JB; Sabaté M; Kaiser C; Brugaletta S; de la Torre Hernandez JM; Galatius S; Cequier A; Eberli F; de Belder A; Serruys PW; Valgimigli M
    Catheter Cardiovasc Interv; 2017 May; 89(6):994-1002. PubMed ID: 27527508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Outcomes and Cost-Effectiveness of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease: Three-Year Follow-Up of the FAME 2 Trial (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation).
    Fearon WF; Nishi T; De Bruyne B; Boothroyd DB; Barbato E; Tonino P; Jüni P; Pijls NHJ; Hlatky MA;
    Circulation; 2018 Jan; 137(5):480-487. PubMed ID: 29097450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angina and associated healthcare costs following percutaneous coronary intervention: A real-world analysis from a multi-payer database.
    Ben-Yehuda O; Kazi DS; Bonafede M; Wade SW; Machacz SF; Stephens LA; Hlatky MA; Hernandez JB
    Catheter Cardiovasc Interv; 2016 Dec; 88(7):1017-1024. PubMed ID: 26774951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and economic effectiveness of percutaneous ventricular assist devices for high-risk patients undergoing percutaneous coronary intervention.
    Shah AP; Retzer EM; Nathan S; Paul JD; Friant J; Dill KE; Thomas JL
    J Invasive Cardiol; 2015 Mar; 27(3):148-54. PubMed ID: 25740967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A targeted approach to reducing overutilization: use of percutaneous coronary intervention in stable coronary artery disease.
    Behnke LM; Solis A; Shulman SA; Skoufalos A
    Popul Health Manag; 2013 Jun; 16(3):164-8. PubMed ID: 23113635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Percutaneous Ventricular Assist Devices: A Health Technology Assessment.
    Health Quality Ontario
    Ont Health Technol Assess Ser; 2017; 17(2):1-97. PubMed ID: 28232854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.